StockNews.AI
EVGN
StockNews.AI
180 days

Evogene Schedules Fourth Quarter 2024 Financial Results Release

1. Evogene announces Q4 2024 earnings release on March 6, 2025. Conference call scheduled. 2. Investors must pre-register via Zoom. Online replay available on website. 3. Evogene leverages AI in biotech and ag chemicals. Focus on efficient development. 4. Subsidiaries include Biomica, Lavie Bio, AgPlenus, and Casterra Ag. Diverse applications noted.

5m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements are routine; only unexpected results tend to create volatility. Historically, scheduled reports cause limited immediate price shifts unless surprises occur.

How important is it?

Although important, the event is a routine earnings release. Its impact on EVGN's price depends entirely on the financial outcomes relative to market expectations.

Why Short Term?

Earnings releases typically drive short-term market reactions. Similar events have led to transient stock price movements.

Related Companies

Nasdaq:EVGNTASE:EVGN
Zoom conference call scheduled for March 6, 2025, 9:00 AM ET , /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's website a few days after. About Evogene: Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including: Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI; Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI. For more information, please visit: www.evogene.com. Contact [email protected]Tel: +972-8-9311901 Logo - https://mma.prnewswire.com/media/1947468/4576969/Evogene_Logo.jpg SOURCE Evogene WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News